13F Pro Quality Score

59.2/100

Rank #943 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

16.1/100

Balance Sheet

23.0/100

Earnings Quality

93.9/100

Free Cash Flow

99.4/100

Institutional Flow

61.1/100

Revenue Scale

15.5/100

Dilution Risk

9.7/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Unusual Activity in SEPN

Events flagged as statistical outliers against SEPN's own multi-year baseline — not fixed dollar thresholds.

SEPN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Septerna, Inc. (SEPN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SEPN at 59.2/100 on a 32-signal composite quality model, placing it at rank #943 of 2,961 stocks — the top half of the AI-ranked universe. SEPN scores in the top quartile across free cash flow (99.4), revenue growth (99.3), earnings quality (93.9). Areas of concern include revenue scale (15.5) and profitability (16.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Septerna, Inc. reports quarterly revenue of $26.7M, net income of $-13.0M, free cash flow of $-22.2M. Top institutional holders of SEPN by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TRV GP V, DRIEHAUS CAPITAL MANAGEMENT, based on the most recent SEC filings. SEPN trades on the Nasdaq exchange and files with the SEC under CIK 1984086. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SEPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Septerna, Inc. directly from SEC EDGAR. Septerna, Inc.'s 13F Pro composite quality score has ranged between 5 and 59 since 2025, currently 59.2 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

Fun facts about Septerna, Inc.

Quirks, history, and lore behind SEPN — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the biotech capital of the world.
  • 2
    The Numbers
    A pre-revenue startup with no approved drugs yet — its balance sheet is essentially cash runway and R&D spend, typical of early-stage biotech IPOs.
  • 3
    The History
    Founded in the early 2020s and went public relatively recently, raising capital to pursue a target class that dominated drug discovery conversations for decades but remained stubbornly hard to crack.
  • 4
    The Secret
    The company is laser-focused on G protein-coupled receptors (GPCRs) — a massive and historically undruggable family of proteins involved in nearly every disease area imaginable.
  • 5
    The Lore
    GPCRs already account for roughly a third of all approved drugs, yet most of the family remains untouched — this company's whole bet is that new structural biology tools finally make the rest accessible.
  • 6
    The Giveaway
    Its name is a nod to the word "septet" — a wink at the seven transmembrane helices that define every GPCR on earth. Seven helices, one obsession.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$26.7M

Net Income

Q2 2026

$-13.0M

Free Cash Flow

Q2 2026

$-22.2M

ROIC

Q2 2026

-17.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4174.5% YoY
$46.0MFY 2025
FY22 FY23 $151.0KFY24 $1.1MFY25 $46.0M

Net Income

+31.9% YoY
$-48.9MFY 2025
FY22 FY23 $4.2MFY24 $-71.8MFY25 $-48.9M

Operating Income

+15.5% YoY
$-68.3MFY 2025
FY22 FY23 $2.1MFY24 $-80.8MFY25 $-68.3M

EPS (Diluted)

+84.8% YoY
$-1.10FY 2025
FY22 FY23 $0.02FY24 $-7.26FY25 $-1.10

Total Assets

+30.6% YoY
$596.2MFY 2025
FY22 FY23 $130.9MFY24 $456.6MFY25 $596.2M

Op. Cash Flow

+263.3% YoY
$110.2MFY 2025
FY22 FY23 $-38.7MFY24 $-67.5MFY25 $110.2M

Free Cash Flow

+257.6% YoY
$109.7MFY 2025
FY22 FY23 $-41.6MFY24 $-69.6MFY25 $109.7M

Get alerted when SEPN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Septerna, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of SEPN

Companies Similar to SEPN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BCRX

BIOCRYST PHARMACEUTICALS INC

53
AI score
Similar quality profile · 10 shared holders
TVTX

Travere Therapeutics, Inc.

54
AI score
Similar quality profile · 10 shared holders
TARS

Tarsus Pharmaceuticals, Inc.

52
AI score
Similar quality profile · 11 shared holders
ANAB

ANAPTYSBIO, INC

45
AI score
Similar quality profile · 11 shared holders
DCTH

DELCATH SYSTEMS, INC.

54
AI score
Similar quality profile · 2 shared holders
XERS

Xeris Biopharma Holdings, Inc.

54
AI score
Similar quality profile · 5 shared holders
TNGX

Tango Therapeutics, Inc.

23
AI score
Similar quality profile · 12 shared holders
RYTM

RHYTHM PHARMACEUTICALS, INC.

33
AI score
Similar quality profile · 14 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put SEPN on your watchlist

Track score changes the day Septerna, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is SEPN a good stock to buy?

13F Pro's AI-powered analysis of Septerna, Inc. (SEPN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SEPN are available on the SEPN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SEPN is classified as a small company.

Which hedge funds own SEPN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SEPN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Septerna, Inc.'s investment landscape.